Spectral Medical Inc. provided an update on the Company's Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion ("PMX") in a randomized controlled trial of adults treated for endotoxemia and septic shock. Enrollment: Robust enrollment activity continuing throughout 2024: 105 patients enrolled at end of April 2024; Record monthly enrollment with seven patients enrolled in April; 24 patients enrolled in 2024 so far - represents the most robust enrollment rates since the start of the Tigris study; With 45 patients to full enrollment, the Company is entering the final push to fully enroll and finish the Tigris trial; To support sustained enrollment, Spectral hosted an in-person Investigator Meeting March 12th & 13th in conjunction with the 29thInternational Conference on Advances in Critical Care Nephrology in San Diego; In-person meeting well attended with multiple stakeholders present, including: principal investigators and clinical research coordinators from existing and new trial sites; CRO, Beaufort; and representatives from the Company's strategic partner Baxter Trial Sites: Continued progress opening additional high quality clinical sites; Recently onboarded the University of Virginia; Two pending sites in the pipeline finalizing contracting and training; Spectral clinical team focused on trial site management activities to ensure that Tigris sites have the support and resources to enroll patients as efficiently as possible.